Transfer reproducible analytical chemistry and preclinical toxicology seamlessly into scalable pilot and commercial OEM batch manufacturing.
In modern biopharmaceutical and nutraceutical product commercialization, raw botanical potency must be balanced with absolute toxicological characterization. An uncharacterized safety profile is the primary cause of regulatory rejection at FDA NDI, EMA herbal monographs, and China NMPA filings.
Our acute safety framework incorporates OECD 420 (Fixed Dose Procedure), OECD 423 (Acute Toxic Class Method), and OECD 425 (Up-and-Down Procedure). We evaluate compound bioavailability, immediate target-organ vulnerability, and maximum tolerated dose (MTD) in rodent models.
Every trial outputs comprehensive physiological tracking, macroscopic necropsy, and median lethal dose (LD50) stratification, establishing rigorous safety thresholds for initial clinical and consumer exposure.
Evaluating long-term systemic exposure in line with OECD 407 and OECD 408 protocols. We monitor complete hematological profiles, serum clinical chemistry, urinalysis, and histopathology across 30+ isolated tissues.
These long-term studies isolate the No Observed Adverse Effect Level (NOAEL) and Benchmark Dose (BMD), delivering the empirical baseline essential for human clinical dose extrapolation and dietary ingredient margin-of-safety calculations.
Botanical complex matrices require meticulous evaluation to rule out DNA reactivity and chromosomal disruption. We execute the standard 3-tier genotoxicity evaluation battery:
1. Bacterial Reverse Mutation (Ames Test, OECD 471) across 5 Salmonella & E. coli strains.
2. In Vitro Mammalian Cell Micronucleus Test (OECD 487) or Chromosomal Aberration (OECD 473).
3. In Vivo Rodent Erythrocyte Micronucleus Assay (OECD 474) for definitive in-body clearance.
| Toxicology Study Module | Guiding International Guideline | Key Biomarkers & Endpoints | Critical Regulatory Submission Impact |
|---|---|---|---|
| Acute Oral Systemic Toxicity | OECD TG 423 / 425, EPA OPPTS 870.1100 | Clinical signs, behavioral alterations, gross necropsy, LD50 cutoff | GHS Chemical Classification, SDS safety labeling, Phase 1 starting dose |
| 28-Day / 90-Day Sub-Chronic | OECD TG 407 / 408, US FDA Redbook 2000 | ALT, AST, ALP, BUN, Creatinine, Organ-to-body weight ratios, Histology | Determines NOAEL / LOAEL, GRAS dossiers, US FDA NDI safety justification |
| Bacterial Reverse Mutation (Ames) | OECD TG 471, ICH S2(R1) | Histidine/Tryptophan reversion counts in TA98, TA100, TA102, TA1535, TA1537 | Mandatory screening for mutagenic impurities and phytochemical safety clearance |
| In Vitro Skin/Eye Irritation & Corrosivity | OECD TG 439 (RhE), OECD TG 492 (EpiOcular) | Cellular viability via MTT assay, tissue morphology disruption | EU Cosmetic Regulation (EC) No 1223/2009, China CSAR safety dossiers |
| Safety Pharmacology (Core Battery) | ICH S7A & ICH S7B | hERG patch clamp, telemetry ECG, respiratory plethysmography, FOB | Investigational New Drug (IND) approval, Cardiovascular & CNS clearance |
Safety parameters vary drastically depending on jurisdiction and commercial category. Our OEM toxicity case studies are precision-tailored to satisfy the distinct review metrics of the world's most rigorous regulatory authorities.
For brands entering North America under DSHEA, introducing a botanical active synthesized via novel extraction solvents requires either a New Dietary Ingredient (NDI) notification or a Generally Recognized as Safe (GRAS) dossier.
Our OEM toxicity package delivers the exact toxicological benchmark data demanded by the FDA review board: 90-day oral toxicity in Sprague-Dawley rats, full ICH genotoxicity panel, and calculated Acceptable Daily Intake (ADI) modeling.
Modernizing traditional Chinese formulas into botanical pharmaceutical entities under US FDA 505(b)(2) or EMA Well-Established Use provisions demands preclinical toxicology that bridges batch-to-batch variation.
We perform multi-batch chromatographic fingerprint safety correlations, pharmacokinetic-toxicokinetic (TK) co-evaluations, and safety pharmacology covering central nervous, cardiovascular, and respiratory systems.
Following China's Cosmetic Supervision and Administration Regulation (CSAR) and EU Regulation 1223/2009, new cosmetic raw ingredients must undergo intensive non-animal safety assessments.
We deploy validated 3D reconstructed human epidermis (RhE) models, corneal epithelium eye irritation assays, local lymph node assays (LLNA:BrdU), and photo-toxicity assessments to ensure seamless global ingredient registration.
Translational pharmacology is moving rapidly toward New Approach Methodologies (NAMs), artificial intelligence, and non-animal alternatives. MedGence integrates traditional in vivo excellence with high-throughput computational tools.
Using deep learning structure-activity relationships (QSAR) and chemical fingerprint databases (over 400,000 botanical constituents), we screen target structures for mutagenic alerts, hepatotoxicity liabilities, and hERG inhibition prior to synthesis or extraction.
This early-stage computational derisking reduces unnecessary animal testing cycles, cutting preclinical development discovery expenses by over 45%.
Pioneering the application of Liver-on-a-Chip and Gut-Kidney fluidic co-cultures to evaluate phytochemical secondary metabolites. Organ-on-a-chip mimics physiological shear stress and multi-tissue metabolic clearance.
This technology provides unprecedented cross-species translation data, accurately determining whether drug-induced liver injury (DILI) observed in rodents is clinically relevant to human patients.
Moving beyond phenotypic organ weights to molecular transcriptomics and high-resolution mass spectrometry metabolomics. We map the entire biological perturbed pathway (KEGG) under botanical exposure.
Identifying early gene expression markers for oxidative stress, mitochondrial uncoupling, and DNA repair activation ensures unassailable safety dossiers for regulatory bodies worldwide.
When research laboratories are decoupled from commercial manufacturing plants, scale-up failure rates exceed 38%. Extraction parameters, thermal degradation of secondary metabolites, and unexpected precipitation during scale-up can render initial laboratory toxicology invalid.
At MedGence (Yineng Pharma), our Changsha R&D Innovation Center works hand-in-glove with our GMP-certified pilot and commercial extraction facilities across Hunan and adjacent botanical supply clusters:
Eliminate adulteration risks at source. We control botanical provenance across authentic production regions (Daodi herbs), eliminating heavy metals, microcystins, and pesticide residues from day zero.
The exact extraction, macroporous resin purification, and spray-drying parameters developed during the toxicology study are directly applied to commercial OEM production equipment under strict Non-Disclosure.
Capitalize on China's world-leading analytical supply chain ecosystem. Complete an entire 90-day sub-chronic and ICH genotoxicity package in 6–8 months, compared to 14–18 months in Western facilities.
Real-world examples of how MedGence resolved complex toxicological liabilities and accelerated commercial market clearances for global botanical leaders.
Challenge: A Tier-1 pharmaceutical group sought to modernize an 8-herb cough & respiratory traditional formula. Regulatory submission stalled due to trace pyrrolizidine alkaloids (PAs) known to present genotoxic and hepatotoxic risks.
Solution: MedGence redesigned the counter-current extraction process using molecularly imprinted solid-phase extraction (MISPE) coupled with HPLC-MS/MS limit of quantitation (LOQ < 1 ppb). We then ran a targeted 90-day rat toxicity study and Ames test on the purified fraction.
Outcome: Proven absence of DNA adducts and no liver micro-vacuolation. Received hospital preparation registration and successful Phase II clinical clearance.
Challenge: An international dietary supplement brand required an emergency safety dossier after receiving an FDA inquiry letter questioning the liver safety profile of an 85% enriched botanical polyphenol extract.
Solution: MedGence conducted a rapid GLP-compliant 28-day repeated oral toxicity study alongside a liver enzyme kinetic assay and in vitro micronucleus testing. In parallel, our CDMO team standardized batch-to-batch solvent residue limits.
Outcome: Established an undeniable NOAEL of 1,200 mg/kg bw/day, giving a 120-fold margin of safety. FDA NDI clearance was successfully achieved without additional clinical holds.
Regulatory toxicology dossiers succeed or fail based on data integrity. Our test facilities operate strictly under Good Laboratory Practice (GLP) philosophies and international harmonized standards.
All analytical equipment (HPLC, LC-MS/MS, GC-MS) operates under automated audit-trail data systems preventing retrospective editing or unrecorded runs.
An autonomous Quality Assurance Unit (QAU) inspects every study protocol, live experimental phase, raw data capture sheet, and final summary report.
Histopathological paraffin blocks, histological slides, and wet tissue samples are preserved under humidity-controlled environments for 10+ years for verification.
Final safety reports delivered in dual English/Chinese formatted strictly in CTD (Common Technical Document) Module 4 preclinical structures for instant filing.
Clear, definitive answers to questions frequently asked by pharmaceutical procurement heads, research directors, and global safety toxicologists.
Select any preclinical module or contact manufacturing solution below to access full study specifications, equipment capabilities, and pilot batch availability.
Whether you are evaluating a novel plant species, answering an FDA NDI inquiry, or scoping CDMO commercial pilot production, our toxicologists and analytical scientists are ready to evaluate your brief.
